Skip to content

Biosimilars news

Biosimilars Canada has compiled a list of news stories from Canada and abroad about biosimilars that may be of interest to readers. These links to third-party websites are provided for informational purposes only, and do represent an endorsement from our organization. Biosimilars Canada’s statements and news releases are available here.

Ontario can save $155 million annually with switch to biosimilars

In this CFRB Newstalk 1010 interview Biosimilars Canada President Jim Keon discusses how Ontario can save money and support pharmaceutical investment through the implementation of a biosimilars switching policy.

Read more

Nova Scotia becomes sixth jurisdiction to implement biosimilar switching

As the Generics Bulletin reports, half of Canada’s provinces have now announced biosimilar switching policies.

Read more

Nova Scotia becomes fifth Canadian province to implement a biosimilar switching program

Report from the AJMC Center for Biosimilars on Nova Scotia’s new biosimilar switching initiative.

Read more

Switch to biosimilar drugs may save N.S. millions of dollars

CBC News coverage of the announcement of Nova Scotia’s biosimilar switching policy, which is expected to save the province more than $13 million annually.

Read more

New Brunswick Adds Insulin Aspart to its Biosimilar Switching Policy

New Brunswick recently expanded its biosimilar switching policy. Patients on New Brunswick’s public drug plan who take NovoRapid insulin aspart will need to switch to an insulin aspart biosimilar by May 31, 2022.

Read more

Quebec Adds Insulin Aspart to its Biosimilar Switching Policy

Quebec has expanded its biosimilar switching policy. Effective February 2, patients on Quebec’s public drug plan who take NovoRapid insulin aspart will need to switch to an insulin aspart biosimilar by July 5, 2022.

Read more
1 2 3 14